Iridium-based anticancer reagents are receiving increasing attention for their high cytotoxicity. Herein, by activating CeH bonds in the well-known antioxidant α-phenyl-N-tert-butylnitrone (PBN), we synthesized and characterized a series of new iridium complexes. Complex 1-AMP exhibited the best antiproliferation activity towards human ovarian cancer A2780 cells. The azide group in complex 1-AMP underwent the Cu(I)-catalysed azide −alkyne cycloaddition (CuAAC) reaction and the resulting fluorescent imaging in cells suggested it mainly accumulated in mitochondria. In comparison, to eliminate cytotoxicity of Cu(I) catalyst, we conducted a reaction between complex 1-AMP and a commercialized dye via strain-promoted alkyne-azide cycloaddition (SPAAC) reaction in live cells, confirming its targeting mainly in the mitochondria. Iridium-based anticancer complexes containing a nitrone ligand and azide group may offer a useful tool to probe the mechanism of metallodrugs.
Introduction
Recently considerable progress has been achieved in catalytic metallodrug development, including catalytic organoiridium (III) complex [1] [2] [3] , ruthenium(II) sulfonamido ethyleneamine complexes [4] , ruthenium carbene complexes [5] and ruthenium arene complexes [6] . These metal catalysts are effective in inhibiting cancer cell growth and cellular metabolic processing [7, 8] , especially for target-directed catalytic metallodrugs [9] through conjugation of a redox-reactive catalytic metal centre to an appropriate targeting domain [10] [11] [12] [13] [14] . However, in the development of catalytic metallodrugs, current challenges include insufficient rates of target inactivation [9] and cellular nucleophilic toxicity [15] . These pioneering works, contributed by Sadler, Dyson, Cowan and others, suggested that efficient targeting of metallodrugs is still essential. Representive metal complexes targeting different organelles in recent reports include photodynamic therapy agents, such as luminescent or phosphorescent iridium(III) complexes targeted to mitochondria [16, 17] , ruthenium(II) polypyridyl complexes targeted to lysosomes [18] and some iridium complexes targeted to autophagic lysosomes [19] . Therefore, imaging and tracking metal complexes is of crucial importance for mechanistic understanding.
However, it remains challenging to track non-fluorescent metallodrugs. The well-known. Clinical platinum drugs [20] , which are generally considered to form exchange-inert complexes with genomic DNA [21, 22] . Recently, DeRose et al. reported the post-treatment modification of Pt(II) complexes, showing nuclear and intense nucleolar localization using a bioorthogonal Cu(I)-catalysed azide−alkyne cycloaddition (CuAAC) reaction in cells [23, 24] . Inspired by DeRose's results, post-treatment of catalytic iridium complexes with azide modification reacted with alkyne-fluorophore via Cu(I) catalysis appears to be a promising approach for studying the mechanism and targeted location of iridium complexes.
Interestingly, fluorogenic reactions in which non-or weakly fluorescent reagents produce highly fluorescent products can be exploited to detect a broad range of compounds [25] . Click chemistry is widely used in many aspects, including nanoparticles, cell-cell interations and protein labeling [26] [27] [28] . The common units in click chemistry include azide, alkyne and nitrone. Azides are versatile reporters due to their small size and virtual absence from biological systems [29] . They can be conjugated via Staudinger ligation using modified phosphines [30] , CuAAC [31, 32] reaction or a strain-promoted alkyne-azide cycloaddition (SPAAC) reaction [33] , which is attractive because it is rapid and does not require a potentially toxic metal catalyst. The reaction requires strained alkynes, such as difluorinated cyclooctyne (DIFO) [34] , dibenzocyclooctyne (DIBO) [35, 36] and bicyclononyne (BCN) [37] . Geert-Jan Boons reported fluorogenic Fl-DIBO probes for visualizing biomolecules without the need for probe washout [25] .
Inspired by DeRose and Geert-Jan Boons, we set out to modify our previously reported nitrone-ligated organoiridium catalyst [38] with azide to probe the mechanism and targeted location of these iridium complexes.
Results and discussion

Synthesis of iridium-hydride complexes
Cancer cells are usually in a state of increased oxidative stress due to mitochondrial function abnormalities. α-phenyl-N-tert-butylnitrone (PBN) can significantly inhibit the formation of reactive oxygen species (ROS) [39, 40] when introduced into cells. Therefore, an organometallic hydride design combining organoiridium with a PBN group and azide unit exhibited excellent catalytic anticancer activity compared to previous research [38] . Here, we designed, synthesized, spectroscopically characterized and biologically assessed three types of iridium-hydride complexes with PBN ligands in vitro. Based on previous work [38] , the aromatic CeH bonds in the PBN ligands were activated to generate iridium hydride complexes. We selected bidentate arylnitrone ligands based on the structure of PBN and synthesized the nitrone ligand to obtain excellent yields. [38] . All of the synthesized complexes were formed via CeH activation (Scheme. S1). Finally we gained complexes 1-a, 1-b and 1-AMP, which contains acetone, pyridine and 3-(azidomethyl) pyridine (AMP), respectively (Scheme. 1a). And we characterized complex 1-AMP. yields and analytical data for the individual ligands can be found in the Supplemental Information Section.
Anticancer ability and iridium distribution assay
We investigated the iridium complexes 1-AMP and other activities towards various cancer cells and their selectivity for cancer cells, with cisplatin as a positive control. We found that compound 1-AMP has the best activity for human ovarian cancer cells (IC 50 = 0.87 μM), 19.63-fold higher than cisplatin (CDDP in Table 1 ). For almost all iridium complexes, the IC 50 values were lower than that of cisplatin. The free ligand AMP and free PBN ligand 1 displayed no significant anti-proliferative activity towards cancer cells, indicating the combination of iridium with the PBN ligand; AMP was essential for anti-proliferation (Table 1) . Besides, A time course of cell proliferation with 1-AMP treatment confirmed that complex 1-AMP had highest toxicity especially to A2780 cells, when compared to complexes 1-a and 1-b (Fig. 2a and Fig. S1 ). Complex 1-AMP containing isopropyl in PBN ligand and azide group showed the highest activity compared to others. For the next mechanistic experiments, 1-AMP was selected. We found accumulated iridium complex 1-AMP in cells, scattered in the mitochondria, nucleus and cytosome via ICP-MS with 59.4% of the compplex was distributed in the mitochondria (Fig. 1b) .
Mechanism analysis of 1-AMP in A2780 cells
Cancer cells often exhibit a disorder redox metabolism [41] , and normal cells are able to control ROS levels by balancing the generation and elimination of ROS with appropriate scavenging systems [1, 42] . According to the distribution of 1-AMP, mainly in mitochondria, we examined the possible change in ROS caused by mitochondria. An increase in the ROS levels in cells after treated with 1-AMP was observed. The ROS generation capacity of compound 1-AMP was found to be stronger than that of 10 μM Rosup (a reagent that can increase cellular ROS level quickly). When A2780 cells were incubated with various concentrations of 1-AMP, MFI (Mean Fluorescence Intensity) of DCF exhibited a gradually increasing tend (Fig. S2) . Besides, a comparison of ROS level in cells treated with 1-a, 1-b and 1-AMP was presented in Fig.  S2 and Fig. S3 . These results indicated raised cellular ROS could be a possible anticancer mechanism.
Considering iridium accumulation in nuclei (Fig. 1b) , and cell nuclear morphological shrinking after dealt with iridium complexes (Fig.  S10) , we analysed the interaction of 1-AMP with plasmid PcDNA. CD spectroscopy was performed to investigate the interaction of complex 1-AMP with DNA. A significant increase in the intensity of the positive CD band at 262 nm suggested a strong interaction between the DNA and complex 1-AMP. Agarose gel electrophoresis (AGE) exhibited DNA retention in sample pores when binding complex 1-AMP, indicating a tight integration of 1-AMP and DNA (Fig. S5) . To explore the DNA damage target in mitochondria or nuclear, we selected three mitochondrial genes MTI (mitochondrially encoded NADH dehydrogenase 1 MT-ND1), MT2 (mitochondrially encoded ATP synthase 6 MT-ATP6), MT3 (mitochondrially encoded cytochrome c MT-CO2) and three nucleus genes N1 (Fragment from nuclear factor kappa B subunit 1 NFKB1), N2 (Fragment from nuclear transcription factor Y subunit alpha NFYA) and N3 (Fragment from nuclear transcription factor Y subunit beta NFYB). We compared the PCR amplifications on six gene fragments from genome in 1-AMP treated A2780 cells and control cells (no metallodrug was added), which suggested the DNA damage was induced in nucleus when treated with complex 1-AMP. (Fig. S7 ).
Imaging of complex 1-AMP in HeLa cells
A better understanding of iridium in cellular reactivity is essential to designing new and more effective therapeutics and methods of delivery. HeLa cells are always utilized as imaging model cell line for their regular cell morphology. To identify the molecular targets of Ir reagents and based on the recently reported (CuAAC) click reaction for posttreatment Pt(II) complexes in cells [24] , we directly used the azide unit in 1-AMP, and the alkyne fluorophore required for the click reaction was based on the common fluorochrome rhodamine. Encouraged by its apparent enhanced reactivity, we pursued cellular localization studies using fluorescence microscopy. We treated HeLa cells with azide-complex 1-AMP (3 μM, 1 h), washed, fixed and permeabilized the cells, and labelled them with the alkyne-containing rhodamine fluorophore (3 μM,1 h) under CuAAC conditions. This imaging result suggested iridium complexes accumulated in various target parts of cells in a very visible way. The reaction products were mainly located in mitochondria while much less was in nuclear (Fig. 2b) . Importantly, the Cu-free controls showed low fluorescence from nonspecific fluorophore interactions (Fig. 2a) .
However, considering possible copper toxicity to cells under the CuAAC click reaction, we instead used strain-promoted alkyne-azide cycloadditon (SPAAC). Reported tagged dibenzocyclooctyne (DBCO) can undergo fast strain-promoted cycloaddition reactions under catalyst-free conditions with azides, nitrones and nitrile oxides, as well as mono-and di-substituted diazo-derivatives [25, 43] and visualized by fluorescence microscopy. We applied this strategy in HeLa cells. First, we treated cells with complex 1-AMP for 1 h and then added 2 μM DBCO-PET4-Fluor545 to 1-AMP-treated cells and untreated cells as a control at the same time. After the reaction of DBCO with the azide in 1-AMP, we obtained an increasingly obvious fluorescent change in cells with time ( Fig. 3a and b) , while the control cells exhibited very weak fluorescence (Fig. 4a) . We repeated this process and found significant fluorescence discrepancy of 1-AMP treated cells with no treated HeLa cells by both whole cells fluorescence detection and flow cytometry detection methods (Fig. 3) . Flow cytometry results reveal the cellular reaction fluorescence intensity was enhanced about 28 fold than probe DBCO. Cycloadditon reaction products were located in the mitochondria with much fewer observed in nuclei, confirming previous CuAAC imaging results (Fig. 4b) .
Two imaging methods of the iridium complex 1-AMP with an azide group in cells both demonstrated that it is mainly located in mitochondria, consistent with the ICP-MS data (59.4% iridium accumulation in mitochondria). These imaging results display the potential of complex 1-AMP not only for further localization studies of iridium complexes in different cancer cell lines, but also for the ongoing goals of designing and identifying iridium-bound targets using click chemistry.
Conclusions
In summary, we have designed and synthesized a series of new iridium-hydride complexes with a PBN ligand. Complex 1-AMP was found to exhibit the highest antiproliferative activity towards human ovarian cancer cells by inducing ROS and DNA damage. We conducted two imaging experiments based on the azide functional group in complex 1-AMP. First, we imaged the complex 1-AMP by CuAAC reaction with a copper catalyst. Second, a reaction without copper catalyst was performed to eliminate the possible toxicity of copper catalyst. Two imaging results for 1-AMP confirmed that the iridium-hydride complexes are mainly concentrated in the mitochondria, consistent with the ICP-MS data. The complex 1-AMP gathered mainly in mitochondria, which might lead to an imbalance in intracellular redox and catalytic reaction processes resulting in cell death. Complexes with PBN ligands and azide groups may offer a general strategy to probe the mechanism of metal-based anticancer drugs.
Experimental
Materials and instrumentation
All solvents were of analytical reagent grade and purified according to standard Procedures [44] . Chloro(1,5-cyclooctadiene) iridium(I) dimer was purchased from Sinocompound. AgSbF 6 was purchased from Alfa Aesar. 4-Chlorobenzaldehyde, 4-(2-pyridinyl)benzaldehyde, Nisopropyl-hydroxylamine hydrochloride, 3-picolyl chloride hydrochloride, 3,3-dimethylbut-1-ene, triphenylphosphine, Na 2 SO 4 and NaHCO 3 were purchased from Adamas. Sodium azide was purchased from Xiya Reagent. All these chemicals were used without further purification.
Nuclear magnetic resonance (NMR) spectra were acquired on Bruker 400 MHz AVANCE III for 1 H NMR and 13 C NMR at 298 K using deuterated solvents. Chemical shifts (δ, ppm) were reported relative to tetramethylsilane (TMS) as the internal standard and the coupling constants are indicated in hertz (Hz). ESI-MS spectra were recorded on a Mariner System 5304 mass spectrometer. TLC was performed on glass-backed silica gel sheets (silica gel HG/T2354-92 GF254) and visualized under UV light (254 nm). Column chromatography was performed using silica gel (300-400 mesh).
Syntheses of 1-a, 1-b, 1-AMP and related ligands 4.2.1. Syntheses of related ligands (Z)-1-(4-chlorophenyl)-N-isopropylmethanimine oxide (ligand 1).
A mixture of 4-chlorobenzaldehyde (605 mg, 4.3 mM), N-isopropylhydroxylamine hydrochloride (528 mg, 4.73 mM), Na 2 SO 4 (1832 mg, 12.9 mM), and NaHCO 3 (1084 mg, 12.9 mM) were added to CH 2 Cl 2 (10 mL), and the reaction mixture was stirred and refluxed under an inert atmosphere of N 2 for approximately 48 h. The resulting mixture was filtered, and the solvent was then removed under vacuum [38] . The solid was rinsed with petroleum ether, then dried in vacuum to furnish a white solid (782 mg, 92%).
3-(azidomethyl)pyridine (AMP) (ligand 2). To A solution of 3-Picolyl chloride hydrochloride (200 mg, 1.25 mM) and sodium azide (120 mg, 1.83 mM) in DMSO-water solvent (1,1, 2 mL) and the reaction was stirred in the air for 16 h at 50°C. Sodium biocarbonate was used to quench it and the combined fractions were obtained after extraction with CH 2 Cl 2 (3 × 10 mL). Then the organic layer was washed with water and dried by with MgSO 4 , filtered and evaporated in vacuum to reveal a brown oil (82 mg, 49%).
3-Butynyl Rhodamine-B Ester (RhB-Alkyne). To A solution of rhodamine-B (1.30 g, 2.70 mM) in dry CH 2 Cl 2 (40 mL) was added 3-butyn-1-ol (0.25 g, 3.56 mM), N, N′-dicyclohexylcarbodiimide (0.84 g, 4.07 mM), and 4-dimethylamino-pyridine (0.40, 0.33 mM) and the reaction was stirred in the dark for 18 h at rt. The purple reaction mixture was washed with H 2 O (3 × 30 mL) and the organic layer was evaporated to dryness in vacuum [45] . The purple oil was purified via flash column chromatography on silica gel (CH 2 Cl 2 : MeOH = 20:1). The solvent were evaporated in vacuum to reveal a purple solid (522 mg, 39%). pyridine (81 mg, 0.60 mM), and dry CH 2 Cl 2 (2 mL). The reaction mixture was stirred and refluxed under an N 2 atmosphere for approximately 12 h. The resulting mixture was diluted with diethyl ether and filtered, and the residue was rinsed with diethyl ether to obtain a yellow solid.
Cancer cell growth inhibition assay
A stock solution of the new iridium complexes and cisplatin were first prepared in DMSO and then serially diluted with media to the desired test concentration. In vitro growth inhibition was performed using a CCK-8 cell proliferation and activity assay kit according to the supplier's instructions. Briefly, 5000 cells per well were seeded in 96-well plates. The cells were preincubated at 298 K in a 5% CO 2 humidified atmosphere for 12 h, and supernatants were removed by suction and washed with PBS twice carefully. Then, 100 μL of media containing different concentrations of the new Iridium (III) complexes and cisplatin were incubated for 48 h, with cisplatin assayed as a positive control. To ensure the reliability of the data, each set contained four parallel hole concentrations. Subsequently, 10 μl CCK-8 was added to each well, and the incubation continued for an additional 3 h. The OD value was measured using an ELISA microplate reader at 450 nm. The IC 50 (concentration of drug resulting in 50% cell growth inhibition) was calculated as the concentration of tested compound using ORIGINPRO 8 statistical software. The IC 50 values for all of the new synthesized iridium complexes were calculated from dose-survival curves, which were obtained using a water-soluble WST-8 (2-(2-methoxy-4-nitrophenyl) -3-(4-nitrophenyl) -5-(2,4-benzene disulfonate) -2H-tetrazolium monosodium salt) assay kit (CCK-8 kit) for drug treatment.
Detection of iridium accumulation of 1-AMP in cells by ICP-MS
A2780 cells were plated at a density of 1 × 10 6 cells/10 mm Petri dish with 9 mL of DMEM media for 24 h. Then the cells were treated with 5 μM Ir complex 1-AMP for 3 h. The drug-containing medium was removed, and the cells were washed with PBS for three times, trypsinized, and counted. The cytosomal, nuclear, and mitochondrial fractions were prepared using a KeyGen Mitochondria/Nuclei Isolation Kit. Collected cells were resuspended with 1.5 mL Lysis buffer, transferred to a glass homogenizer for fully grinding, then centrifuged for 5 min at 4°C, 800 g. The precipitation was transferred to 0.5 mL Medium Buffer A upon 1 mL Medium Buffer B at 4°C, followed by 1000 g for 10 min to get a pure nucleus precipitation. Then the nuclear part was stored in a Nuclear Store Buffer. Homogenate supernatant was then uploaded upon 0.5 mL Medium Buffer C at 4°C, followed by 15,000 g for 10 min. After centrifugation, supernatant contained cytoplasm components and precipitation was Mitochondria. Mitochondria was then stored with Mitochondria Store Buffer. Finally iridium contents were quantified by ICP-MS analysis.
Cellular ROS detection
We used the fluorescent probe 7-dichlorodihydro-fluoresce indiacetate (DCFH-DA) to study the level of ROS in A2780 cells induced by compound 1-AMP. After entering cell, DCFH-DA can be hydrolyzed to DCFH and DCFH can be oxidized to fluorescent DCH by cellular ROS. Thus, DCF content can represent cellular ROS level. 50,000 A2780 cells were seeded and incubated in 6 well plates for 24 h. Then cells were treated with 0 μM, 5 μM, 7.5 μM, 10 μM 1-AMP for 1 h and 5 μM Rosup (a reagent that can increase cellular ROS level quickly) as positive control. Then we removed the medium, adding 10 μM DCFH-DA for 30 min in 37°C, washing 3 times and finally collected cells for flow cytometry detection at 488 nm channel. After just 1 h of drug exposure, we observed a dramatic increase in ROS levels in cells treated with compound 1-AMP compared to untreated cells.
Cell nuclear morphological shrinking with DAPI dye
A2780 cells were cultured on a glass-bottom dish for appropriate density and treated with complex 1-AMP (2 μM) for 24 h, using cells without compound 1-AMP as control. Cells were washed with PBS twice, immobilized with 4% paraformaldehyde for 20 min, washed with PBS twice, incubated with DAPI dye solution for 10 min and washed with PBS twice. Then, samples were detected under fluorescence microscope (Fig. S5). 4.7. Circular dichroism spectroscopy and agarose gel electrophoresis of DNA with complex 1-AMP To solutions of PcDNA plasmid DNA (74 μg/mL) in sodium phosphate buffer (20 mM, pH 7.4), the appropriate complex 1-AMP was added in a total volume of 300 μL. The mixtures were incubated for 4 h at room temperature. CD spectra were recorded on a Jasco J-815 spectropolarimeter using a quartz cuvette 385 with a path length of 1 cm with 10 accumulations per spectrum. For Agarose gel electrophoresis, 5 μL general PcDNA plasmid DNA plasmid were taken (105 μg/mL)) to blend with 2 μM, 5 μM, 10 μM 1-AMP for 4 h at room temperature using plasmid DNA as a negative control. We observed the position of the DNA using 10% agarose gel electrophoresis. Table S2 ) and two genomes (1-AMP group and control group). PCR procedures were as follows: 95°C DNA denaturation, 60°C primers annealing and 72°C fragment extension. Finally we observed PCR products by Agarose gel electrophoresis.
Imaging of 1-AMP in HeLa cells via Cu(I)-catalysed azide − alkyne cycloaddition reaction
Human cervical cancer cell line (HeLa) cells from the American Type Culture Collection (ATCC) were cultured in DMEM media with 10% FBS at 37°C and 5% CO 2 for the appropriate density, seeded onto microscope cover slips and treated with 1-AMP complexes (5 μM) for 1 h. Cells were then washed with PBS twice, fixed with 4% paraformaldehyde for 20 min, permeabilized with Triton-X100 for 15 min and washed twice with 3% BSA for 10 min. The CuAAC reaction occurred with 0.5 mM CuSO 4 , 5 mM THPTA, 25 mM sodium ascorbate, 100 mM phosphate buffer and 5 μM alkyne-Rhodamine for 2 h at room temperature. Cells were washed with 3% BSA for 5 min, Triton-X100 twice for 10 min, mitochondria tracker Green MTG (From KenGEN BioTECH) (1 μL) for 25 min and PBS twice for 10 min. Finally, slides were incubated with one drop ProLong Diamond Antifade Reagent (Sigma) for 24 h at room temperature. A control group without Cu(I) was prepared following the same labelling protocol. Cells were observed using a Fluorescence Microscope ZEISS Axio Observer Z1 and Apotome2 software. For the fluorogenic process, we seeded 1000 cells onto microscope cover slips for 24 h, then cells underwent 2 μM 1-AMP treatment for 1 h, with AMP treated cells and no complex treated cells as the control group, incubated with DBCO-PET4-Fluor 545 for different time periods. Fluorescent change was tracked with time for 72 min, images collected at different period. Cells were observed using a Fluorescence Microscope ZEISS Axio Observer Z1 and Apotome2 software.
For location, 1000 HeLa cells were seeded onto microscope cover slips and treated with 1-AMP complexes (5 μM) for 1 h then DBCO-PET4-Fluor 545 (2 μM) for 30 min. Cells were then washed with PBS twice, fixed with 4% paraformaldehyde for 15 min. Hoechst 33,342 for 15 min and PBS twice for 10 min, then Mitochondria tracker Green MTG (From KenGEN BioTECH) (1 μL) for 25 min and PBS twice for 10 min. Cells were observed using a Fluorescence Microscope ZEISS Axio Observer Z1 and Apotome2 software. 
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